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A significant aspect of the control of cellular zinc in eukarya is its subcellular
re-distribution. One of the four human vesicular zinc transporters, ZnT8,
supplies the millimolar zinc concentrations of insulin granules in pancreatic
b-cells, affecting insulin processing, crystallisation and secretion. ZnT8 has a
transmembrane and a C-terminal cytosolic domain; the latter has important
functions and purportedly mediates protein–protein interactions, senses
cytosolic zinc and/or channels zinc to the transport site in the transmembrane
domain (TMD). A common variant W325R in the C-terminal domain
(CTD) increases the risk to develop type 2 diabetes and affects autoantibody
specificity in type 1 diabetes. To investigate the differences between the two
protein variants, we purified and biophysically characterised both variants of
the ZnT8 CTD [R325 variant of ZnT8 CTD (aa267–369) (ZnT8cR) and
W325 variant of ZnT8 CTD (aa267–369) (ZnT8cW)]. The domains fold inde-
pendently of the TMD. Remarkably, the ZnT8cW variant (diabetes protec-
tion in the full-length protein) is less thermostable than the ZnT8cR variant
(diabetes risk in the full-length protein). The ZnT8cW monomers associate
with higher affinity. Both CTD variants bind zinc with a stoichiometry that
differs from bacterial homologues, emphasising the limitation of the latter as
models for the structure and function of the human proteins. The relatively
small but reproducible differences between the two ZnT8 CTD variants begin
to provide a molecular basis for the different diabetes susceptibility caused
by the full-length ZnT8 proteins.
Introduction
Perturbations of cellular zinc metabolism through muta-
tions in dozens of proteins are implicated in a growing
number of human diseases [1]. Among these proteins
are transporters that regulate the passage of Zn2+
across biological membranes. Belonging to two families,
ZIPs (Zrt/Irt-like Protein, SLC39A) and ZnTs (zinc
transporter, SLC30A), they transport zinc into and out
of the cytosol, respectively [2]. Humans have 14 ZIPs
and 10 ZnTs, which are expressed differentially in tis-
sues and have different cellular localisations [2].
Cellular zinc compartmentalisation is controlled by
these two families of zinc transporters and by metal-
lothioneins [3]. A subgroup of four transporters
(ZnT2, 3, 4 and 8 in mammals) of the cation diffusion
facilitator (CDF) superfamily exports zinc ions from
the cytosol into intracellular vesicles. One of them,
ZnT8 (SLC30A8), is highly expressed in the membrane
of the dense insulin secretory granules of pancreatic b-
cells [4]. It supplies zinc for the storage of insulin as a
crystalline hexamer and for other aspects of the
Abbreviations
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biochemistry occurring in the granules [5]. ZnT8 also
has a yet to be defined role in glucagon secretion in pan-
creatic a-cells and is present in some other tissues [6].
A structural issue of ZnT8 with significant functional
implications is an SNP resulting in two major variants
with either Arg (R) or Trp (W) at position 325 in the
C-terminal domain (CTD). Both variants are common
in human populations (R: 60%–95%; W: 5%–40%) [7].
A third variant encoding Gln is far rarer in populations
and will not be discussed here. Remarkably, the major
R325 variant increases the risk of developing type 2
diabetes (T2D) [5]. These observations have led to the
postulate that higher zinc transport activity is related to
b-cell health and that activation of ZnT8 might be a
way of improving b-cell health [8]. However, this inter-
pretation has now come into question, as the R325
T2D-risk allele apparently has the higher transport
activity [9], providing a plausible explanation why
humans heterozygous for one of several loss-of-function
mutations in SLC30A8 are protected against diabetes
[10]. Based on 3D homology models, the R/W325
replacement in ZnT8 is not directly involved in the CTD
zinc-binding site(s). However, it has functional conse-
quences and a relatively large impact on human health,
as the differences in transport activity of the two vari-
ants confer a 15% increased risk of developing T2D for
each allele of the risk R325 form [9,11].
There is no 3D structure of a eukaryotic CDF pro-
tein; therefore, concepts of how these vesicular ZnTs
work are based entirely on the 3D structures of prokary-
otic CDF homologues. The crystal structure of the
Escherichia coli protein YiiP revealed a dimer with a
transmembrane domain (TMD) and a CTD [12]. The
dimer binds eight zinc ions: two in sites A, which are the
primary TMD transport sites, two in sites B between
the domains with an unknown function and four in two
binuclear sites C at the dimer interface of the CTD. The
CTDs are believed to be metal sensors, working by an
allosteric mechanism that links the occupancy of sites C
by zinc (Kd = 24 lM, measured in proteoliposomes) to
induction of a conformational change of the CTD,
which is then transmitted to the TMD to trigger zinc/
proton antiport [13]. This allosteric regulation of the
TMD by the CTD is thought to be important for full
transporter functionality, as though CTD-truncated ver-
sions of the CDF proteins ZitB from E. coli and CzcD
from Cupriavidus metallidurans were capable of trans-
porting Zn2+ in vivo, their transport activity was
decreased [14]. However, mutations at site C in the
CTD of MntE from Streptococcus pneumoniae did not
affect manganese transport [15]. Additionally, a cryo-
electron microscopy structure of a YiiP homologue
from Shewanella oneidensis does not seem to confirm
the allosteric mechanism of zinc binding; rather this
study suggests that the zinc-binding sites in the CTD are
of such high affinity that zinc is always bound; there-
fore, any conformational changes during transport
occur solely in the TMD [16]. These data suggest that
different CDF CTDs have varying effects on transport
function even among bacterial homologues.
Aside from the structure of the full-length E. coli pro-
tein YiiP, there are three crystal structures of bacterial
CTDs: Thermus thermophilus CzrB [17], Thermo-
toga maritima TM0876 [18] and Magnetospiril-
lum gryphiswaldense MamM [19]. The models of the
bacterial proteins fail to explain the function(s) of the
CTD in the family of mammalian vesicular transporters
for the following reason. While the bacterial proteins
sense and export an excess of zinc, there is no evidence
for an excess of zinc in the cytosol of eukaryotic cells for
export into granules of the secretory pathway. Unless
zinc is made available by some yet unknown mecha-
nism, the cytosolic free zinc ion concentrations are only
hundreds of pM to maximally 1.5 nM, a very small frac-
tion of the ~ 250 lM total cellular zinc concentration
[20,21]. In insulin granules, estimates of free zinc ion
concentrations are 120 nM (pH 6) and total zinc concen-
trations are tens to perhaps even hundreds of millimolar
[22,23]. Thus, for both total and free zinc, ZnT8 has to
work against a concentration gradient of about three
orders of magnitude.
The R325W replacement in ZnT8 generates a differ-
ent epitope for autoantibodies in type 1 diabetes (T1D)
[24] (an issue of protein conformation in the CTD) in
addition to affecting insulin biology in T2D (an issue
thought to relate to zinc transport) [9]. The underlying
question for the basic biological chemistry addressed
here is how these two amino acids affect subunit interac-
tions, dimer dynamics and zinc binding. Thus, biophysi-
cal investigations of the CTDs of ZnT8 would solve a
key issue in b-cell granule biology central to control of
energy metabolism, provide important information
regarding the biology of other zinc-containing vesicles
served by ZnT2–4, and make a significant contribution
to CDF biology in general. Towards this goal, we
expressed both ZnT8cW (ZnT8 CTD, aa267–369,
expressing Trp at position 325) and ZnT8cR (ZnT8
CTD expressing Arg at position 325). The two proteins
adopt their predicted fold independent of the presence
of the TMD and have different zinc-binding characteris-
tics compared to their bacterial homologues. Structural
and stability differences between the two CTD variants
affect their dimerisation. Previous deductions made
from the 3D structures of bacterial homologues are
therefore insufficient to explain the properties of the
human proteins in health and disease.
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Results
Bioinformatics structure predictions
Based on a comparison of the primary sequences of
several human and two bacterial CDF CTDs, for
which 3D structures are known, the two ZnT8 CTD
variants (ZnT8cR and ZnT8cW) are predicted to
adopt an abbab fold (Fig. 1A) observed in at least
four bacterial CTDs of homologous zinc transporters.
This fold is characteristic of the ‘heavy metal-asso-
ciated domain’, also called the ferredoxin fold babbab
in different metalloproteins interacting with iron, cop-
per or zinc [25]. Indeed, we predict such a structure
for all mammalian ZnT CTDs with the possible
Fig. 1. Metal-binding and structural motifs in the CTDs of ZnTs/CDFs. (A) Primary sequence comparison between the CTDs of selected
bacterial and human CDFs, indicating both conserved and non-conserved motifs. Protein secondary structure was predicted using JPRED 4
(Materials and methods); a-helices in blue and b-sheets in green. Metal-binding residues are highlighted in red with black text; site 2 of the
binuclear zinc site described in the 3D structure of Escherichia coli YiiP (shown on top) is not conserved in mammalian ZnTs. Metal-binding
residues annotated in the alignment are contributed from one protomer (yellow) or the other protomer (blue) in the dimer. Both metal-binding
sites in E. coli YiiP utilise a water molecule as the fourth ligand in the tetrahedral coordination of each Zn2+ ion. Specific residue numbering is
based on the sequence of the E. coli YiiP protein. The arginine at position 325 in ZnT8 is highlighted in yellow. Residues involved in the charge
interlock (Ch. Int.) are indicated in red text; notably, these residues are only partially conserved (Glu replacing Asp) between the bacterial and
the vesicular ZnT subfamily (ZnT2, 3, 4 and 8). The CXXC motif, which is also specific to vesicular ZnTs, is highlighted in purple. Dileucine motifs
in ZnT2 and 3 are purportedly involved in protein localisation [34]. The ligands forming the purported third weaker zinc-binding site in CzrB [17]
are not indicated. (B) 3D homology model of human ZnT8cR based on Thermus thermophilus CzrB using SWISS-MODEL (Materials and methods),
highlighting the conserved metal-binding ligands in magenta with bound zinc ions in grey and the T2D-risk variant residue R325 in red. The triple
b-sheet face is predicted to form the dimer interface, while residue 325 is located in a loop at the apex of the dimer.
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exception of ZnT9 (Fig. 1A). A 3D model of the
ZnT8cR homodimer based on the structure of T. ther-
mophilus CzrB was constructed (Fig. 1B). The model
predicts that residue 325 is located in a loop which is
in close proximity to the second protomer in the dimer
in the zinc-bound state.
Our analysis further shows that in the CTDs of
human ZnTs, the ligands for a second metal ion in the
binuclear site C are not strictly conserved and, impor-
tantly, the ligand stemming from the other subunit,
His261 in E. coli YiiP, is not conserved (Fig. 1A).
Therefore, an important issue is if the CTDs of these
human transporters bind fewer or even no metal ions
at all. The conservation of only three predicted metal
ligands, that is, two histidines and one glutamate/as-
partate in the vesicular ZnTs (Fig. 1A), raises the
questions of whether the CTDs in these human trans-
porters sense zinc ion concentrations and how the pro-
tomers forming the dimer interact. The metal ligands
that are conserved do not form a bridge between the
two protomer CTDs in the dimer; thus, the CTD
dimerisation-induced conformational change seen upon
zinc binding to the CTD in E. coli YiiP [13] may not
occur and may not have the same consequences in
human ZnTs.
Remarkably, there is a high density of potential
metal binding residues in the C-terminal tail of ZnT8,
including a CXXC motif, which is present only in the
vesicular subfamily of human ZnTs (ZnT2, 3, 4 and
8). This motif is conserved in all verified vesicular ZnT
sequences available from the UniProt database, includ-
ing mouse, rat, cow and frog. The significance of this
motif is not known although CXXC motifs have redox
functions or a metal-binding role in metalloproteins,
such as in some copper chaperones where they can
mediate metal transfer to client proteins [26]. However,
in copper chaperones, this motif is typically in a differ-
ent position in the primary sequence.
A ‘charge interlock’ (Ch. Int.) comprised of Asp207
in the CTD and Lys77 in the TMD is thought to be
important for dimer formation in the full-length E. coli
YiiP protein [13]. However, these residues are not con-
served in non-vesicular human ZnTs (i.e. not ZnT2–4 or
8). The charge of these residues is conserved in vesicular
ZnTs, but Asp207 in the E. coli YiiP CTD is replaced
by Glu in the vesicular ZnT subfamily (Fig. 1A), while
the TMD Lys77 is replaced by Arg.
Protein yield
A typical 2 L bacterial culture (of either variant,
aa267–369 in addition to an N-terminal hexahistidine
tag and a TEV protease cleavage site) yielded ~ 1 mg
of > 95% pure ZnT8 CTD protein (Fig. 2A). Protein
samples were concentrated to ~ 100–300 lM. There is
a tendency for the proteins to aggregate and ultimately
precipitate completely after a period of ~ 2 weeks. To
alleviate the aggregation issues, many buffer con-
stituents and several different E. coli expression strains
were screened; the most effective conditions for expres-
sion of a folded protein were used herein (Materials
and methods). Addition of fresh Tris(2-carboxyethyl)
phosphine hydrochloride (TCEP) during the size
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Fig. 2. Purity and elution profiles of human ZnT8 CTD proteins. (A)
Protein in the minor elution peaks at ~ 160 mL was analysed by SDS/
PAGE and is > 95% pure ZnT8 CTD. Lane ‘M’ contains molecular
weight markers; lane ‘1’ contains purified apo-ZnT8cR; and lane ‘2’
contains purified apo-ZnT8cW. The protein in the major elution peaks
at ~ 95 mL was also analysed by SDS/PAGE (not shown) and is
aggregated ZnT8. (B) Size exclusion chromatogram using a Superdex
S75 26/60 column for ZnT8cR protein and, (C) ZnT8cW protein.
Following calibration of the column (Materials and methods), the
proteins in the fractions eluting at ~ 160 mL have a molecular mass
of 34.9 kDa (calculated ZnT8 CTD monomer mass is 13.3 kDa).
1240 The FEBS Journal 285 (2018) 1237–1250 ª 2018 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies.
ZnT8 C-terminal cytosolic domain D. S. Parsons et al.
exclusion purification step is necessary to obtain a high
yield of pure protein.
The two CTD variants share structural similarities
ZnT8cR and ZnT8cW elute at the same volume in size
exclusion chromatography (160 mL, Fig. 2B,C). Cali-
bration of the Superdex S75 26/60 column with protein
standards (Materials and methods) indicates that both
variant ZnT8 CTD proteins have an apparent molecu-
lar mass of 34.9 kDa. The expected mass of the mono-
mer is 13.3 kDa including the His-tag and TEV
protease site. Native PAGE analyses of the purified
proteins indicate that both variants are dimeric. SDS/
PAGE analysis of the largest peak at 95 mL indicates
that it is aggregated but soluble ZnT8 CTD protein.
The secondary structure of both apo-ZnT8 CTD vari-
ants was investigated using CD spectroscopy; the two
variants yield similar far-UV CD spectra (Fig. 3A).
The spectra did not change significantly upon addition
of two molar equivalents of ZnCl2 or NiSO4, or
replacement of NaCl with KCl. Inserting individual
CD spectra into BeStSel [27], a fold recognition algo-
rithm, showed that the two variants contain similar
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Fig. 3. CD spectroscopy of the two human ZnT8 CTD variants. (A) Representative (n = 3) far-UV CD spectra of 0.2 mgmL1 apo-ZnT8cR
(blue) and apo-ZnT8cW (red) variants in 10 mM K2HPO4, 60 mM NaCl, 20 mM sucrose, pH 8. Separate far-UV CD spectra measured in the
presence of two molar equivalents of Zn2+, two molar equivalents of Ni2+ or with KCl replacing NaCl, were not significantly different from
those of the apo-proteins. (B) Protein secondary structure, expressed as %  standard deviation (n = 3), was determined using individual
CD spectra for both apo-ZnT8cR and ZnT8cW variants with the BeStSel algorithm (Materials and methods). The difference in secondary
structure between the two variants is not statistically significant. Helix and sheet content of Escherichia coli YiiP CTD were calculated from
the 3D structure (PDB ID: 2qfi), while turns and other structures could not be readily differentiated.
Temperature (oC)
0 20 40 60 80 100
C
irc
ul
ar
 d
ic
hr
oi
sm
 a
t 2
22
 n
m
 (m
de
g)
–9
–8
–7
–6
–5
–4
–3A
Temperature (oC)
0 20 40 60 80 100
C
irc
ul
ar
 d
ic
hr
oi
sm
 a
t 2
22
 n
m
 (m
de
g)
–10
–9
–8
–7
–6
–5
–4
–3B
Fig. 4. Thermostability of the two human ZnT8 CTD variants. (A) Representative (n ≥ 3) melting curves for apo-ZnT8cR (magenta circles,
Tm = 42.8  0.5 °C) and ZnT8cR with two molar equivalents of Zn2+ (teal triangles, Tm = 54.5  2.1 °C) measuring the change in CD at 222
nm from 6 to 92 °C with a heating rate of 1 °Cmin1. (B) Representative (n = 3) CD melting curves of apo-ZnT8cW (red circles,
Tm = 41.4  0.4 °C) and ZnT8cW in the presence of two molar equivalents of Zn2+ (green triangles, Tm = 51.0  1.8 °C). There are
significant differences between thermal stability of apo-ZnT8cR and apo-ZnT8cW (n = 3, P = 0.013) and between both apo-variants and the
variant in the presence of Zn2+ (for each comparison n = 3, P < 0.001). The difference in stability between the two variants in the presence
of Zn2+ is not statistically significant (P = 0.093).
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helix and sheet content to both each other and the
CTD of the 3D-characterised E. coli homologue YiiP
(Fig. 3B). Thus, as predicted, the secondary structure
and fold are highly conserved.
ZnT8cR is more thermostable than ZnT8cW; Zn2+
stabilises both variants
The thermal stability of both CTD variants in the pres-
ence and absence of ZnCl2 was investigated using melt-
ing analysis by both CD spectroscopy between 6 and
92 °C (Fig. 4A,B) and nano differential scanning fluo-
rimetry (nDSF) between 20 and 85 °C. This type of
DSF utilises intrinsic protein fluorescence; the ratio of
the emission at 350 nm to that at 330 nm as a function
of temperature reveals the point(s) at which the protein
structure changes significantly. There is a significant dif-
ference between the stability of the CTD variants in the
apo (Zn2+-free) form as measured with both CD and
nDSF; the ZnT8cR Tm is 42.8  0.5 °C, whereas the
ZnT8cW Tm is 41.4  0.4 °C (n = 3, P = 0.013).
Remarkably, apo-ZnT8cR (T2D-risk in the full-length
protein) has higher thermostability than apo-ZnT8cW
(T2D-protective in the full-length protein). Both CTD
variants are significantly more stable in the presence of
two molar equivalents of Zn2+; ZnT8cR-2Zn Tm is
54.5  2.1 °C and ZnT8cW-2Zn Tm is 51.0  1.8 °C
(in each comparison n = 3, P < 0.001), but not in the
presence of two molar equivalents of Ni2+. The numeri-
cal difference in stability between the two CTD variants
in the presence of Zn2+ is not statistically significant
(P = 0.093).
The two Trp residues in ZnT8cW are in different
local environments
ZnT8cW contains two tryptophan residues (W306 and
W325), whereas ZnT8cR contains only one (W306).
The emission spectrum (kEx = 295 nm) of ZnT8cR
provides information on the tryptophan residue shared
by both variants (i.e. W306). Therefore, by subtracting
the ZnT8cR emission spectrum from that of ZnT8cW,
information about W325 in ZnT8cW can be obtained
(Fig. 5). The emission maximum of ZnT8cR was
340 nm, corresponding to W306, while that of
ZnT8cW was 345 nm. The emission maximum of
W325, calculated by subtracting the ZnT8cR spectrum
from that of ZnT8cW, is 350 nm. For comparison, a
pure N-acetyl-DL-tryptophan solution measured in the
same buffer has an emission maximum at 363 nm. The
degree of blue shift of a tryptophan residue’s emission
from that of pure tryptophan in solution depends on
how hydrophobic the local environment is. In the
ZnT8cW protein, W325 is therefore in a less
hydrophobic environment than W306, and therefore
more solvent accessible.
The amino acid at position 325 affects dimer
formation
The homodimerisation affinities of both ZnT8 CTD
variants were measured using microscale thermophore-
sis (MST) in the presence of EDTA, eliminating any
influence of divalent metal ions (Fig. 6). Titrating
100 nM labelled apo-protein with 180 lM–5.5 nM
(ZnT8cR) or 124 lM–3.8 nM (ZnT8cW) unlabelled
apo-protein yielded homodimerisation Kd values of
4.3  1.3 lM for ZnT8cR and 1.8  0.1 lM for
ZnT8cW. This difference is statistically significant
(n = 3, P = 0.034). Thus, the dimerisation of ZnT8cR
(T2D-risk in the full-length protein) occurs with less
affinity than ZnT8cW (T2D-protective in the full-
length protein) in the presence of EDTA. The direc-
tionality of this difference is opposite to that observed
for the thermostability of the two forms.
The amino acid at position 325 does not directly
affect metal binding
Based on sequence analysis, the expected divalent
metal ion binding capacity for ZnT8 CTDs is one ion
per monomer (Fig. 1A). The two variant apo-proteins
(10 lM protein) were incubated with 0–10 molar equiv-
alents of Zn2+ and subjected to gel filtration to remove
any loosely bound zinc. Inductively coupled plasma
mass spectrometry (ICP-MS) analysis of the apo-ZnT8
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Fig. 5. Fluorescence spectroscopy of the two human ZnT8 CTD
variants. Representative (n = 3) fluorescence spectra of ZnT8cW
(red squares) and ZnT8cR (blue circles) protein, both 2.8 lM, in
50 mM Tris/HCl, pH 8, 300 mM NaCl (kEx = 295 nm). The ZnT8cR
variant contains one tryptophan residue (W306), while the ZnT8cW
variant contains two (W306 and W325). Therefore, by subtracting
the ZnT8cR signal from that of ZnT8cW the fluorescence spectrum
of W325 was obtained (magenta diamonds).
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CTD proteins incubated with no additional Zn2+
showed that 0.21  0.07 (n = 6) divalent metal ions
(Zn2+ and Ni2+) were residually bound per monomer.
The vast majority of this residual metal load (> 90%)
was contributed by Ni2+. Supplementing up to 10 molar
equivalents of Zn2+ indicates that both variants bind
approximately three Zn2+ ions per monomer; an aver-
age of 2.6  0.4 Zn2+ ions bind to ZnT8cR, whereas
3.2  0.5 Zn2+ ions bind to ZnT8cW (Fig. 7). This dif-
ference between the two variants is not statistically sig-
nificant (n = 3, P = 0.156). Upon addition of 4–10
molar equivalents of Zn2+, the small amount of Ni2+
residually bound to both CTD variants was displaced.
A competition assay with the chromophoric chelat-
ing agent Zincon shows similar results for both ZnT8
CTD variants (Fig. 8A,B). When titrated with zinc in
buffer alone, 70 lM Zincon is saturated with 70 lM
ZnCl2 and an initial increase in absorbance at 620 nm
is measured upon addition of 1 lM ZnCl2. Zincon has
a Kd of 214 nM for a 1 : 1 complex with zinc at pH 8
[28]. However, when competing with 5 lM apo-ZnT8
CTD (either variant), the initial increase in absorbance
is not seen until 10 lM Zn2+ is added, indicating that
both ZnT8 CTD variants contain two Zn2+-binding
sites that have a tighter affinity than 214 nM and thus
outcompete the zinc binding to Zincon. Following this
initial 10 lM ZnCl2, an additional 75 lM ZnCl2 is
required to saturate zinc binding to Zincon in the pres-
ence of 5 lM apo-ZnT8 CTD protein (both variants).
Thus, both variants have an additional zinc site with
low affinity competing directly with Zincon. When
both ZnT8 CTD protein variants have their cysteines
blocked by alkylation with iodoacetamide, only 5 lM
ZnCl2 is required to measure a change in absorbance
at 620 nm. This result indicates that cysteines in the
C-terminal tail, which contains three cysteines, consti-
tute one of the two high affinity binding sites that out-
compete the binding of zinc to Zincon. With protein
modified by iodoacetamide (both variants), an addi-
tional 75 lM ZnCl2 is still required to saturate the Zin-
con, indicating that the lower affinity site is not lost
upon cysteine alkylation.
A dityrosine bond does not form between ZnT8
CTD protomers
Using a specific anti-dityrosine antibody, an inter-pro-
tomer dityrosine bond in the CTDs of ZnT3 and
ZnT4 homodimers was detected [29]. Dityrosine bonds
have a high quantum yield at 407 nm when using an
excitation wavelength of 325 nm, well above the exci-
tation maximum of individual tyrosine residues. There
is one tyrosine residue in ZnT8 CTD (Y284) although
it is not at the same position as the three tyrosine resi-
dues involved in ZnT3 and ZnT4 homodimerisation.
Nevertheless, using fluorescence spectroscopy, we
could not detect any emission associated with a dity-
rosine in either ZnT8 CTD variant.
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Fig. 6. Dimerisation of the two human ZnT8 CTD variants.
Representative (n = 3) MST traces for dimerisation of ZnT8 CTD
protein. Fluorescently labelled apo-ZnT8cR (100 nM, magenta
circles) was titrated (in the presence of 1 mM EDTA) with
unlabelled apo-ZnT8cR protein (180 lM–5.5 nM), yielding a
homodimerisation Kd of 4.3  1.3 lM. Fluorescently labelled apo-
ZnT8cW (100 nM, teal triangles) was titrated (in the presence of
1 mM EDTA) with unlabelled apo-ZnT8cW protein (124 lM–3.8 nM),
with a homodimerisation Kd of 1.8  0.1 lM. There is a significant
difference between the homodimerisation Kd of each variant in the
presence of EDTA (n = 3, P = 0.034).
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Fig. 7. Zinc stoichiometry of the two ZnT8 CTD variants. Fraction
of the maximum Zn2+ content of 10 lM ZnT8cR (teal diamonds)
and ZnT8cW (red circles) following incubation with 0–10 molar
equivalents of Zn2+ and subsequent gel filtration to remove
unbound Zn2+. Protein concentration was determined
spectrophotometrically (Materials and methods). The intersection
points in the titration data indicate that ZnT8cR binds Zn2+ with a
stoichiometry of 2.6  0.4 per monomer, whereas ZnT8cW binds
3.2  0.5 per monomer. The difference between the two variants
is not statistically significant (n = 3 for both variants, P = 0.156).
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Discussion
The mammalian ZnTs are thought to function with
the Zn2+/H+ antiport mechanism elucidated for ZnT1
and the bacterial homologues [30]. The antiport is
likely coupled to induced conformational changes that
alternately open the channel inward or outward as
shown for the bacterial homologues [13,16]. In con-
trast to the E. coli YiiP protein, which has a zinc/cad-
mium selectivity filter in the TMD with one histidine
and three aspartates, the mammalian ZnTs utilise two
histidine and two aspartate side chains to transport
zinc specifically [31]. Amongst mammalian ZnTs (with
the exception of ZnT10, which has an asparagine
instead of one of the two aspartates in the TMD and
accordingly transports manganese in addition to zinc
[32]), the zinc transport site and the overall structure
of the TMD are highly conserved [3]. The CTD, how-
ever, is much more variable and is thought to be criti-
cal in the evolution of these transporters for different
functions, such as the subset of four vesicular trans-
porters, ZnT2–4 and ZnT8. This subgroup supplies
exocytotic vesicles with zinc for various purposes, such
as synaptic vesicles (ZnT3) involved in neurotransmis-
sion [33] and vesicles in mammary epithelial cells
(ZnT2) that supply zinc in the milk of lactating women
[34]. How ZnTs acquire and deliver sufficient zinc to
exocytotic vesicles is an unresolved biochemical issue.
Despite the lack of high sequence homology between
CTDs in mammalian ZnTs, various structural features
are conserved, for instance the overall fold. Based on
prediction of secondary structure and CD data, both
ZnT8cR and ZnT8cW form the abbab structure
observed in the structure of E. coli YiiP, and most
other ZnT CTDs are predicted to adopt this structure
(Fig. 1A). Referred to as a ‘ferredoxin’ fold as it was
originally found in iron proteins, it is also commonly
found in copper proteins, in particular copper chaper-
ones [25]. However, the metal-binding sites are at dif-
ferent positions in these proteins.
Due to the predicted location of ZnT8 residue 325
at the CTD dimer interface (Fig. 1B), the R325W
replacement is likely to affect dimer formation and sta-
bility. A significant difference in dimer association
between the two human ZnT8 CTD variants was
detected in this investigation. The directionality of the
difference was not expected, however; despite an
increased thermostability of ZnT8cR, its dimerisation
affinity was lower than that of ZnT8cW. Collectively,
these data show that both dimer formation and stabil-
ity are affected in the two CTD variants. The 2.9-A
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Fig. 8. Zinc affinity of the two ZnT8 CTD variants. (A) Zinc
binding to ZnT8cR in competition with Zincon. Measuring
absorbance of 620 nm, it takes 70 lM ZnCl2 to saturate 70 lM
Zincon in 50 mM HEPES, pH 8, 300 mM NaCl, 100 mM sucrose
(black squares). In competition with 5 lM apo-ZnT8cR (blue
diamonds), no signal at 620 nm is detected until 10 lM ZnCl2 is
added, revealing two high affinity zinc-binding sites in ZnT8cR
which outcompete Zincon. An additional 75 lM ZnCl2 is required
to fully saturate Zincon, identifying one lower affinity (~ lM) site
that directly competes with Zincon. When ZnT8cR is reduced
and incubated with iodoacetamide for 1 h prior to the Zincon
assay (red triangles), only 5 lM ZnCl2 is required to elicit the
initial signal at 620 nm. An additional 75 lM ZnCl2 is required to
saturate the Zincon. Thus, when the cysteines are blocked by
alkylation, ZnT8cR retains one high affinity and one low affinity
Zn2+-binding site. B, Zinc binding to ZnT8cW in competition with
Zincon. ZnCl2 titration of Zincon alone in HEPES buffer (black
squares), in competition with apo-ZnT8cW (orange diamonds),
and in competition with ZnT8cW modified with iodoacetamide
(magenta triangles), demonstrating that ZnT8cW also contains
two high affinity and one low affinity zinc binding sites, and that
one high affinity binding site is lost upon alkylation of the three
cysteines in ZnT8cW.
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crystal structure of E. coli YiiP revealed that the CTD
dimer interface is highly charged and that in the
absence of bound Zn2+, the repulsive charges in the
dimer cause the protomers to swing apart [13]. The
exchange of the charged R325 residue for uncharged
W325 may disrupt this charge interaction in ZnT8,
and may explain the biophysical differences in the two
variant CTDs observed. Neither the Arg nor the Trp
at position 325 are conserved among the ZnTs, or even
among species; murine and rat ZnT8 encode Gln325.
The position is at a variable loop between the con-
served secondary structures.
The identity of residue 325 in ZnT8 alters the speci-
ficity of ZnT8 autoantibodies in T1D [24], with sera
from at least 22% of patients reacting with one of
either R325 or W325 antibodies but not the other. Pre-
vious studies expressing ZnT8 CTDs to investigate
antibody epitopes did not prove that the protein folds
correctly [35]. A properly folded protein may be cru-
cial for presenting the correct 3D epitope to the anti-
body. Indeed, the ZnT8 autoantibody epitope has
been confirmed to be conformational rather than lin-
ear [24]. Therefore, the availability and characterisa-
tion of the folded CTDs may be important for
efficient antibody production.
Another model for the dimerisation in mammalian
vesicular ZnTs, namely the formation of a dityrosine,
has been advanced for ZnT3 [29]. The ZnT8 CTD
contains one tyrosine (Y284) although its location in
the primary sequence is not conserved with any of the
tyrosine residues implicated in ZnT3 homodimerisa-
tion. We found no evidence for dityrosine bond forma-
tion in either ZnT8 CTD variant. A charge interlock
with residues from both the TMD and CTD serves as
a hinge in the dimerisation of full-length CDF proteins
[13]. The charge interlock CTD residues (albeit Glu
replacing Asp207 and Arg replacing Lys77 in YiiP) are
conserved in vesicular ZnTs (Fig. 1A) but, because of
the absence of the TMD, isolated CDF CTDs do not
interrogate this aspect of intersubunit linkages. Intrigu-
ingly, these charge interlock residues are not conserved
in non-vesicular ZnTs, suggesting that the intersubunit
linkages differ amongst mammalian ZnTs.
A characteristic feature of CTDs in bacterial CDFs is
two zinc-binding sites per monomer, harbouring four zinc
ions in the dimer [12] (although the T. thermophilus CzrB
CTD contains an additional weak zinc-binding site [17]).
One of these sites utilises ligands from both protomers,
therefore bridging between the dimer subunits, while the
other(s) are formed of ligands from only one protomer.
Both metal-binding sites utilise a water molecule as the
fourth ligand in the tetrahedral coordination of the Zn2+
ions. Remarkably, the ligands for the intersubunit metal-
binding site are not conserved in the human ZnTs
(Fig. 1A). Specifically, a ligand corresponding to His261
is missing. This is the only residue contributing a metal-
binding ligand from the second protomer in the dimer in
E. coli YiiP, and is involved in the CTD conformational
changes seen upon zinc binding, or ‘zinc sensing’, when
the cytosolic zinc concentration reaches an upper thresh-
old [13]. The primary biological function of these bacterial
transporters is to protect the cytosol from zinc overload,
and current evidence suggests micromolar Km values for
transport [13]. The problem with this model for the four
vesicular ZnTs (ZnT2–4 and 8) is that there is only
picomolar free zinc available in the cytosol of human
cells, and the total vesicular zinc concentrations are high
millimolar. Therefore, either the vesicular ZnT CTDs are
able to sense much lower cytosolic zinc concentrations
than their bacterial homologues, for which there is no evi-
dence at present, or the role of the CTD is different from
that of the bacterial proteins and not involved in sensing
zinc directly, as suggested by our findings.
Our measurements show that both apo-ZnT8 CTD
variants form stable dimers. Addition of two molar
equivalents of zinc significantly increases the stability
of both variant CTDs, without significantly altering
their secondary structures. Following zinc addition up
to saturation with 10 molar equivalents of zinc, three
zinc ions were tightly bound per protein monomer.
The difficulty in relating the metal binding to a partic-
ular binding site in the CTD stems from the fact that
the expressed protein has a hexahistidine tag. It was
possible to remove this tag, but the resulting protein
was unstable and precipitated, rendering further exper-
imentation impossible. ZnT8 has three C-terminal cys-
teine residues, including a CXXC motif that has been
shown to bind zinc in the metal-binding domains of
E. coli ZnTA [36] and Synechocystis PCC 6803 ZiaA
[37], and copper in copper chaperones [38]. Amongst
human ZnTs, the CXXC motif is only conserved in the
vesicular subfamily (Fig. 1A). Competition assays per-
formed with the chromophoric zinc chelator Zincon
and protein modified with iodoacetamide (Fig. 8)
reveal that one of the two < 214 nM affinity zinc-bind-
ing sites identified in both ZnT8 CTD variants is
formed of the C-terminal cysteines. The small amount
of residual Ni2+ that was bound to both variant apo-
proteins was only displaced upon supplementing the
protein with 4–10 molar equivalents of zinc. This
agrees with published data indicating that the His-tag
has a higher affinity for Ni2+ than it does for Zn2+
[39]. Protein-bound His-tags bind Ni2+ with an affinity
of ~ 700 nM [40]. These data support the hypothesis
that the low affinity site (approximately micromolar),
identified in both ZnT8 CTD variants with the Zincon
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competition assay, is contributed by the His-tag. There-
fore, our metal-binding data can be reconciled with the
prediction from the sequence alignment that indeed
maximally only one metal ion binds with high affinity
at the canonical interface site in the protein as isolated,
the second with high affinity at the C-terminal cysteines
and the third with lower affinity to the His-tag.
A recent report, in which the activity of ZnT8 reconsti-
tuted in liposomes was investigated, concluded that the
transport activity is dependent on the lipid environment,
and inferred that the lipid environment affects zinc load-
ing during insulin granule biogenesis [9]. This report also
noted that the T2D-risk R325 ZnT8 variant consistently
showed a small increase in zinc transport activity com-
pared to the T2D-protective W325 variant, which was
revealed only with specific lipid compositions of the lipo-
somes. In accordance with higher transport activity, it
was noted that human islets with the R325 ZnT8 variant
had a higher zinc content [41]. Another report on ZnT8
transport in Xenopus laevis oocytes did not detect a dif-
ference in transport kinetics between the ZnT8 R/W325
variants, supporting the conclusion that the liposome
lipid composition may be crucial for revealing differences
between the two variants [42].
There are two main conclusions. First, the mam-
malian vesicular ZnTs are significantly different from
bacterial CDF ZnTs in their CTD zinc binding. The loss
of the subunit-bridging ‘sensing’ zinc binding site in the
CTD, the additional high affinity zinc binding at the C-
terminal cysteines and the disparity between the very
low concentration (pM) of free cytosolic zinc and the
very high (mM) total zinc levels found in secretory vesi-
cles, strongly suggest that the sensing of excess cytosolic
zinc and the concomitant transport in bacteria would
need to function differently in mammalian systems sup-
plying zinc to exocytotic vesicles. Bacterial zinc expor-
ters need only function when the cell is experiencing
high and/or toxic levels of zinc, whereas loading of insu-
lin and other secretory vesicles, for instance synaptic
vesicles by ZnT3 [33], must occur under conditions of
normal cytosolic zinc concentrations. Second, this is the
first report detailing that the W325R mutation causes
significant differences in ZnT8 CTD dimer formation
and stability. How or even if these effects in the CTDs
lead to the altered transport function of the full-length
proteins reported elsewhere [9], and ultimately to the rel-
atively large increased risk of developing T2D for carri-
ers of the R325 variant, will require further
investigation. That the T2D-risk ZnT8 R325 variant is
the more active form of the transporter suggests that
people with the R325 variant may have an increased
zinc content in their insulin granules as indicated by the
data on human islets [41]. This increased granular zinc
uptake may deplete cytosolic zinc and affect b-cell func-
tion. If so, it may need to be ameliorated with a higher
dietary zinc intake [43].
Materials and methods
Materials
Tris(2-carboxyethyl)phosphine hydrochloride, HEPES,
iodoacetamide, Zincon sodium salt, NaCl, K2HPO4,
KH2PO4, MgCl2, ZnCl2 and N-acetyl-DL-tryptophan were
purchased from Sigma Aldrich (St. Louis, MO, USA);
Tris-base and SDS from Severn Biotech (Kidderminster,
UK); DTT and PMSF from Thermo Fisher Scientific (Wal-
tham, MA, USA); Tween-20 and NiSO4.6H2O from Acros
Organics (Geel, Belgium); sucrose from Merck Millipore
(Burlington, MA, USA); IPTG from Promega (Madison,
WI, USA); L,L-dityrosine dihydrochloride from Santa Cruz
Biotechnology (Dallas, TX, USA); 5,50-dithiobis(2-nitro-
benzoic acid) (DTNB; Ellman’s reagent) from Invitrogen
(Carlsbad, CA, USA); EDTA from Cambridge Bioscience
(Cambridge, UK); LB media powder from MP Biomedicals
(Santa Ana, CA, USA); and imidazole from Apollo Scien-
tific (Stockport, UK).
Protein expression and purification
The sequence encoding residues 267–369 of human R325
ZnT8 (ZnT8cR; any residue numbering refers to full-length
human ZnT8 long isoform, Ensembl transcript SLC30A8-
002) was optimised for E. coli expression and the cDNA
synthesised by DNA2.0 (Menlo Park, CA, USA). It was
inserted into pET6H encoding an N-terminal hexahistidine
tag and a TEV protease cleavage site. Mutagenesis to pro-
duce the W325 variant (ZnT8cW) was carried out by
Mutagenex (Suwanee, GA, USA) using PCR-based substi-
tution, followed by sequence verification of the inserts of
both plasmids. The two plasmids were transformed into
E. coli strain SoluBL21TM (AMS Biotechnology, Abingdon,
UK) and grown at 30 °C in LB media containing
100 lgmL1 ampicillin until the OD600 reached 0.60. Cells
were then kept at 16 °C on an orbital shaker (G25 Incuba-
tor Shaker, New Brunswick, Edison, NJ, USA; 210 r.p.m.)
for 30 min before protein expression was induced with
0.5 mM IPTG and the cells kept at 16 °C and at 210 r.p.m.
for an additional 42 h. Cells were harvested by centrifuga-
tion and resuspended in 10 mL lysis buffer [50 mM Tris/
HCl, pH 8, 100 mM NaCl, 100 mM sucrose, 5 mM DTT,
2 mM MgCl2, 1 mM PMSF, 5 UmL1 DNase (Thermo
Fisher Scientific)] until a homogenous solution was
obtained. The homogenate was diluted 1 : 6 with equilibra-
tion buffer [50 mM Tris/HCl, pH 8, 100 mM NaCl, 100 mM
sucrose, 2 mM DTT, 20 mM imidazole, containing one
tablet of Complete ULTRA mini EDTA-free protease inhi-
bitors (Roche, Basel, Switzerland)], and sonicated (Model
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2000U, Ultrasonic Power Corp. (Freeport, IL, USA); +285
output, 0.5 s1 pulse) in an ice-water bath for 20 s pulse
and 40 s rest settings for a total of 15 min, followed by
centrifugation at 45 000 g for 40 min at 4 °C. The 60 mL
supernatant was added to 2 mL of pre-equilibrated Ni2+
affinity gel (Sigma Aldrich) and incubated end-over-end on
a roller at 4 °C for 40 min. After centrifugation at 500 g
for 1 min at 4 °C, the pellet was washed three times with
equilibration buffer containing 500 mM NaCl. The bound
protein was eluted in five 1 mL washes with elution buffer
(50 mM Tris/HCl, pH 8, 500 mM NaCl, 100 mM sucrose,
2 mM DTT, 300 mM imidazole). The eluate was loaded onto a
Superdex S75 26/60 column (GE Healthcare, Chicago, IL,
USA) equilibrated with purification buffer (50 mM Tris/HCl,
pH 8, 300 mM NaCl, 100 mM sucrose, 100 lM TCEP) using a
flow of 2.2 mLmin1 and a column temperature of 4 °C. The
column was calibrated with yeast alcohol dehydrogenase,
bovine serum albumin, bovine erythrocyte carbonic anhydrase
and aprotinin. To produce ZnT8c apo-protein, 2 mM TCEP
and 1 mM EDTA were added to the 10 mL fractions from size
exclusion chromatography and then concentrated to
~ 0.5 mL using a 15 mL 3 kDa MWCO centrifugal concen-
trator (Merck Millipore). Samples were stored in this state for
up to 1 week at 4 °C. Up to 0.5 mL protein was then diluted
309 with EDTA- and TCEP-free buffer (exact constituents
dependent on assay to be carried out as given in the corre-
sponding experiments) and concentrated to 0.5 mL with the
same centrifugal concentrators, performing this dilution/con-
centration step at least three times. Reduced apo (zinc-free)
protein was then used fresh within 1 day. Concentrated sam-
ples were analysed using 16% (w/v) Tris-glycine SDS/PAGE
(Thermo Fisher Scientific) [44]. Protein samples used for MST
were purified as above, except that an amine-free buffer
(50 mM potassium phosphate, pH 8, 300 mM NaCl, 100 mM
sucrose, 100 lM TCEP) was used for the size exclusion chro-
matography.
Determination of protein concentration
The concentration of the protein samples was determined
spectrophotometrically using a modified Bradford assay
[45] with Bio-Rad protein assay reagent (Hercules, CA,
USA). Bovine serum albumin (Thermo Fisher Scientific)
dissolved in purification buffer was used as the standard.
The accuracy of the determination was corroborated by
spectroscopic measurements, using extinction coefficients of
13 980 M1cm1 for ZnT8cW and 8480 M1cm1 for
ZnT8cR (calculated from the primary protein sequence).
CD spectroscopy
CD spectra were acquired on a Chirascan Plus spectrome-
ter (Applied Photophysics, Leatherhead, UK). Far-UV
spectra in the 195–260 nm range were recorded using a
0.5 mm path length cuvette, a bandwidth of 2 nm, a step
size of 1 nm and a time-per-point of 1 s. Spectra were
taken at 20 °C. For all spectra, the protein concentrations
were 0.2 mgmL1 in 10 mM potassium phosphate, pH 8,
60 mM NaCl, 20 mM sucrose. Protein secondary structure
content based on CD spectra was determined using BeStSel
[27]. Melting analyses involved monitoring the CD signal at
222 nm between 6 and 92 °C at a heating rate of
1 °Cmin1. Separate far-UV spectra and melting analyses
were performed with both variants in the presence of two
molar equivalents of ZnCl2, two molar equivalents of
NiSO4 and by replacing the 60 mM NaCl with 60 mM KCl
to examine any possible influence of the cation.
Nano differential scanning fluorimetry (nDSF)
Samples of 5 lM ZnT8cR and ZnT8cW in 10 mM Tris/
HCl, pH 8, 60 mM NaCl, 20 mM sucrose, 2 mM DTT were
loaded into nDSF-grade standard capillaries (NanoTemper
Technologies, Munich, Germany). Protein unfolding was
measured by detecting fluorescence emission changes at 350
and 330 nm, between 20 and 85 °C at a rate of 1 °Cmin1,
using a Prometheus NT.48 instrument (NanoTemper Tech-
nologies). Protein melting temperatures were calculated by
taking the first derivative of the 350/330 nm ratio, and are
given as the average of at least three samples  standard
deviation.
Microscale thermophoresis (MST)
Samples of 20 lM ZnT8cR or ZnT8cW were labelled with
amine-reactive Monolith NT.115 labelling kit Red-NHS
(#MO-L001; NanoTemper Technologies) as per the manu-
facturer’s instructions. Labelled proteins were diluted to a
final concentration of 100 nM in 10 mM potassium phos-
phate, pH 8, 60 mM NaCl, 20 mM sucrose, 100 lM TCEP,
1 mM EDTA, 0.05% (v/v) Tween-20. ZnT8cR-Red and
ZnT8cW-Red were titrated with 180 lM–5.5 nM unlabelled
ZnT8cR or 124 lM–3.8 nM unlabelled ZnT8cW, respec-
tively. All experiments were performed using a Monolith
NT.115 instrument (NanoTemper Technologies) at 25 °C
in standard-coated capillaries (NanoTemper Technologies).
Binding affinities were calculated using MO.Affinity Analy-
sis software (NanoTemper Technologies) and are expressed
as the average of at least three separate measurements 
standard deviation.
Inductively coupled plasma mass spectrometry
(ICP-MS)
Concentrated apo-protein samples of both variants were pre-
pared and diluted with ≥ 18.2 MO.cm water (ELGA Lab-
Water, High Wycombe, UK). These samples were analysed
for zinc and nickel with ICP-MS (Perkin Elmer Life Science,
Waltham, MA, USA, model NexION 350D) and were
shown to have reduced metal content compared with protein
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samples that had not been incubated with additional TCEP
and EDTA.
To measure zinc-binding stoichiometry, ZnT8cR and
ZnT8cW samples were prepared in 10 mM Tris/HCl, pH 8,
60 mM NaCl and 20 mM sucrose. Samples of each isoform
were diluted to 10 lM. Each protein sample was then incu-
bated with 0, 1, 2, 4 or 10 molar equivalents of Zn2+
(ZnCl2) for 10 min at 21 °C, followed by gravity-flow gel
filtration using PD MiniTrap G-25 desalting columns (GE
Healthcare) to remove excess zinc. Samples were then
diluted with ≥ 18.2 MO.cm water and analysed for zinc
and nickel using ICP-MS.
Fluorescence
Fluorescence measurements were taken at 21 °C using a
Perkin Elmer LS50 fluorimeter. Separate ZnT8cR and
ZnT8cW samples were diluted to 2.8 lM in 50 mM Tris/
HCl, pH 8, 300 mM NaCl in a volume of 2 mL. Emission
spectra (kEx = 295 nm) were collected between 300 and
400 nm at a 100 nmmin1 scan rate. Emission spectra for
3 lM N-acetyl-DL-tryptophan solutions were collected in the
same buffer. Emission spectra were recorded between 300
and 450 nm (kEx = 325 nm) for examining the presence of
a dityrosine bond, using 1 lM L,L-dityrosine dihydrochlo-
ride in 1 M Tris/HCl, pH 8 as a positive control.
Assessing redox state of the cysteines and
alkylation of cysteine residues
DTNB (Ellman’s reagent) was used to quantify the free
sulfhydryls present in the protein samples, following the
manufacturer’s instructions, using 50 mM HEPES, pH 8,
300 mM NaCl and 100 mM sucrose as the reaction buffer
and the molar extinction coefficient at 412 nm of TNB
(14 150 M1cm1). Protein was diluted to 2 lM and the
production of TNB measured after 15 min. Iodoacetamide
was used to alkylate the sulfhydryls on the cysteine side
chains, as per the manufacturer’s instructions. Alkylation
was confirmed upon measuring no free sulfhydryls in the
protein with DTNB.
Zincon competition assay
Zincon forms a 1 : 1 complex with Zn2+ with a reported
dissociation constant of 214 nM at pH 8 [28]. A stock solu-
tion of Zincon was prepared in ≥ 18.2 MO.cm water,
diluted and the concentration determined at 488 nm using
e488 = 26 900 M
1cm1 and a 0.5 cm quartz cuvette in a
Jenway 7315 spectrophotometer. Zincon was diluted to
70 lM in 50 mM HEPES, pH 8, 300 mM NaCl, 100 mM
sucrose and titrated with ZnCl2, measuring the change in
absorbance at 620 nm. Competition assays between 70 lM
Zincon and 5 lM ZnT8 CTD protein were performed with
both apo-protein and protein modified with iodoac-
etamide. The titration break points and thus the stoi-
chiometries were analysed by extrapolating the linear
portion of the titration and comparing it with the buffer-
only control.
Bioinformatics and molecular modelling
Primary protein sequences were compared using CLUSTAL
OMEGA (EMBL, Heidelberg, Germany) and secondary struc-
ture predictions were carried out using JPRED 4 [46]. The
ZnT8cR homodimer was modelled with SWISS-MODEL
[47] based on the 3D structure of the T. thermophilus
homologue CzrB (PDB ID: 3byr) with two zinc ions
bound, while PyMOL was used for visual representation of
3D structure. CzrB was chosen as the primary basis for the
model rather than E. coli YiiP owing to the availability of
the zinc-bound conformation of CzrB in the SWISS-
MODEL template selection algorithm. Models constructed
based on YiiP and other available bacterial CDF CTDs
returned similar models.
Statistics
All statistical significance was assessed by unpaired Stu-
dent’s t-tests using SIGMAPLOT 14.0 (Systat Software Inc.,
Chicago, IL, USA).
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